ArticleESC heart failure2025
eGFR slope as predictor of mortality in heart failure patients.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Distinct prognostic trajectories of heart failure phenotypes following kidney transplantation.ESC heart failure · 2026Article
- Association of Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate With Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.Kidney medicine · 2026Article
- Dyspnea in heart failure: pathophysiology, clinical assessment, and evidence from clinical trials.Heart failure reviews · 2026Review
- Prediction of cardiac arrest in patients with heart failure in Sweden: a registry study with development of a machine learning model.BMJ open · 2026Observational
- Association between lactate-to-albumin ratio and 28-day mortality in critically ill patients with HFpEF: a retrospectively cohort study.Scientific reports · 2026Article
- Analysis of risk factors for heart failure in patients with type 2 diabetes mellitus and acute ST-segment elevation myocardial infarction after percutaneous coronary intervention.Frontiers in medicine · 2026Article
- Real-World Use of ARNI Within GDMT in HFrEF Patients with and Without Atrial Fibrillation: A Retrospective Analysis of Cardiac and Renal Functions and Clinical Outcomes.Journal of cardiovascular development and disease · 2025Article
- Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Diagnostics (Basel, Switzerland) · 2025Article
- Impact of Kidney Function on the Survival of Patients with Chagas Cardiomyopathy and Implantable Cardioverter Defibrillators.Journal of clinical medicine · 2025Article
- Review
- How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?International journal of heart failure · 2025Review
- eGFR slope as predictor of mortality in heart failure patients.ESC heart failure · 2025Article
- Exploring Potential Causality and Molecular Mechanisms between Heart Failure and Renal Failure: Insights from Mendelian Randomization Studies, the MIMIC-IV Database and the Gene Expression Omnibus Database.Journal of vascular research · 2025Article
- Development and validation of an interpretable machine learning model for predicting the risk of non-cardiac surgery postoperative heart failure: a multicenter study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsHeart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real-world HF patients, assessing eGFR trajectories and their impact on mortality. METHODS AND
resultsRetrospective clinical data of HF patients were processed using natural language processing. Chronic kidney disease (CKD) was evaluated, and eGFR trajectories were analysed using linear mixed-effects models. Cox proportional hazard models were used to evaluate the relationship between baseline variables and mortality, while joint modelling combined eGFR trends and mortality. The dataset comprised 1986 patients, with a mean age of 74.8 years (SD ± 11.7) and 58% male. At the time of HF diagnosis, 58% of patients were diagnosed with CKD, and 39% presented with heart failure with preserved ejection fraction (HFpEF). The median follow-up duration was 3.16 years, during which 399 patients (20%) died. Patients with CKD were significantly older and exhibited a higher prevalence of myocardial infarction (P = 0.048), coronary revascularization (P = 0.004), stroke (P < 0.001), atrial fibrillation (P < 0.001) and type 2 diabetes (P < 0.001). Mortality rates at 1 and 2 years were nearly twice as high in CKD patients compared with those without (P < 0.001). Notably, CKD was significantly less prevalent among survivors (55% vs. 71%, P < 0.001). Key predictors of mortality included older age, beta-blocker use, prior stroke, lower serum haemoglobin levels, and elevated potassium and NT-proBNP levels. Each 10 mL/min/1.73 m
conclusionsCKD is prevalent in a real-world HF population and is an independent predictor of mortality. The current eGFR value and the eGFR slope from the previous year have the potential to be used for assessing individual mortality risk in the clinical follow-up of HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.